Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 18, 2023

SELL
$4.89 - $12.27 $4,890 - $12,270
-1,000 Reduced 83.33%
200 $0
Q2 2022

Sep 06, 2022

BUY
$7.45 - $13.84 $8,940 - $16,608
1,200 New
1,200 $19,000
Q2 2022

Aug 12, 2022

SELL
$7.45 - $13.84 $8,940 - $16,608
-1,200 Closed
0 $0
Q1 2022

Sep 06, 2022

BUY
$9.94 - $12.65 $9,940 - $12,650
1,000 Added 500.0%
1,200 $14,000
Q1 2021

Apr 30, 2021

SELL
$15.07 - $21.71 $90 - $130
-6 Reduced 2.91%
200 $4,000
Q4 2020

Jan 25, 2021

SELL
$12.72 - $16.16 $597 - $759
-47 Reduced 18.58%
206 $3,000
Q4 2019

Jan 17, 2020

SELL
$16.11 - $25.98 $26,210 - $42,269
-1,627 Reduced 86.54%
253 $4,000
Q3 2019

Nov 07, 2019

BUY
$18.28 - $26.91 $22,575 - $33,233
1,235 Added 191.47%
1,880 $35,000
Q1 2019

May 15, 2019

SELL
$14.41 - $19.64 $11,311 - $15,417
-785 Reduced 54.9%
645 $13,000
Q4 2018

Jan 23, 2019

SELL
$12.45 - $23.47 $49,687 - $93,668
-3,991 Reduced 73.62%
1,430 $18,000
Q3 2018

Oct 25, 2018

BUY
$17.57 - $23.95 $25,880 - $35,278
1,473 Added 37.31%
5,421 $0
Q2 2018

Aug 07, 2018

BUY
$11.6 - $19.27 $30,740 - $51,065
2,650 Added 204.16%
3,948 $0
Q1 2018

Jun 03, 2019

BUY
$11.77 - $16.08 $5,296 - $7,235
450 Added 53.07%
1,298 $16,000
Q1 2018

May 09, 2018

SELL
$11.77 - $16.08 $5,296 - $7,235
-450 Reduced 34.67%
848 $0
Q4 2017

Jan 24, 2018

BUY
$11.86 - $14.08 $4,364 - $5,181
368 Added 39.57%
1,298 $0
Q3 2017

Oct 30, 2017

BUY
$12.6 - $16.34 $1,890 - $2,451
150 Added 19.23%
930 $13,000
Q2 2017

Jun 03, 2019

BUY
N/A
6 Added 0.78%
780 $12,000
Q1 2017

Jun 03, 2019

SELL
N/A
-25 Reduced 3.13%
774 $14,000
Q4 2016

Jun 03, 2019

BUY
N/A
699 Added 699.0%
799 $7,000
Q2 2016

Jun 03, 2019

SELL
N/A
-545 Reduced 84.5%
100 $0
Q1 2016

Jun 03, 2019

BUY
N/A
645
645 $13,000

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $262M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Ifp Advisors, Inc Portfolio

Follow Ifp Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.